Clinical trials for Chronic myelomonocytic leukemia
29 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGEarly Phase 1NCT07071155Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · PI: Tania Jain, MD
- RECRUITINGNCT07512882Cohort of Patients With Chronic Myelomonocytic LeukemiaGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGPhase 2NCT06815003Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningCity of Hope Medical Center · PI: Monzr M. Al Malki
- RECRUITINGPhase 2NCT06597734A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmM.D. Anderson Cancer Center · PI: Kelly Chien, MD
- RECRUITINGPhase 1NCT06543381Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical Center · PI: Amandeep Salhotra, MD
- RECRUITINGPhase 3NCT06647862IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · PI: zhijian xiao, PHD
- RECRUITINGPHASE1, PHASE2NCT06159491Pacritinib in CMMLDouglas Tremblay · PI: Douglas Tremblay, MD
- RECRUITINGPhase 1NCT06218628Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionFox Chase Cancer Center · PI: Peter Abdelmessieh, DO, MSc
- RECRUITINGPhase 1NCT06071624Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.Huda Salman · PI: Huda Salman, MD, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT05883956A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaOtsuka Australia Pharmaceutical Pty Ltd · PI: Anoop Enjeti
- ACTIVE NOT RECRUITINGPhase 2NCT05768711Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)Groupe Francophone des Myelodysplasies · PI: Raphaël ITZYKSON, MD/PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05600894Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmNational Cancer Institute (NCI) · PI: Rory M Shallis
- RECRUITINGPhase 1NCT05488548Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological MalignanciesEpigenetix, Inc. · PI: Judy Chiao, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05038592Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesM.D. Anderson Cancer Center · PI: Guillermo M Bravo, MD
- ACTIVE NOT RECRUITINGPhase 3NCT05153226GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATGDKMS gemeinnützige GmbH · PI: Johannes Schetelig, Prof Dr med
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04730258A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLTreadwell Therapeutics, Inc · PI: Gautam Borthakur, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04806906Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS PatientsUniversity of Florence · PI: Valeria Santini, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaM.D. Anderson Cancer Center · PI: Guillermo Garcia-Manero
- ACTIVE NOT RECRUITINGPhase 2NCT04409639Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsUniversity of Utah · PI: Ami Patel, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04550442Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaM.D. Anderson Cancer Center · PI: Guillermo Garcia-Manero
- RECRUITINGPhase 2NCT04239157A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaM.D. Anderson Cancer Center · PI: Guillermo Garcia-Manero
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04493138Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsM.D. Anderson Cancer Center · PI: Guillermo M Bravo
- ACTIVE NOT RECRUITINGNCT07318662Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMMLGuangdong Provincial People's Hospital
- RECRUITINGPHASE1, PHASE2NCT04140487Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmM.D. Anderson Cancer Center · PI: Nicholas Short
- ACTIVE NOT RECRUITINGPhase 2NCT03722407Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionH. Lee Moffitt Cancer Center and Research Institute · PI: Eric Padron, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03770429AZD6738 for Patients With Progressive MDS or CMMLMassachusetts General Hospital · PI: Andrew M Brunner, MD
- RECRUITINGPhase 1NCT03896269CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaM.D. Anderson Cancer Center · PI: Guillermo M Bravo
- ACTIVE NOT RECRUITINGPhase 2NCT01522976Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaNational Cancer Institute (NCI) · PI: Mikkael A Sekeres
- ACTIVE NOT RECRUITINGPhase 3NCT00843882Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaNational Cancer Institute (NCI) · PI: Amit K Verma